all report title image
  • Published On : Jan 2023
  • Code : CMI5486
  • Industry : Pharmaceutical
  • Pages : 169
  • Formats :

The global anticoagulant market was valued at US$ 30,773.2 Mn in 2021 and is forecast to reach a value of US$ 57,337.5 Mn by 2028 at a CAGR of 9.4% between 2022 and 2028. The anticoagulant market is experiencing strong growth due to the growing prevalence of chronic disease and rise in demand for anticoagulants across the world. Moreover, rise in focus on the development of novel anticoagulants and growing geriatric population across the globe are expected to boost the growth of the market. However, factors such as side effects associated with anticoagulants and stringent government regulations are expected to hamper growth of the global anticoagulant market.

Global Anticoagulant Market: Regional Insights

Based on geography, the global anticoagulant market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period due to the increase in incidence of chronic diseases (especially cardiovascular diseases) and rise in adoption of novel oral anticoagulants (NOACs) in the region. For instance, according to the American Heart Association (AHA), October 2021 report, over 2,300 people in the United States die due to cardiovascular diseases each day, an average of one death every 38 seconds. Thus, with the increase in prevalence of cardiovascular diseases (CVDs), demand for anticoagulants is also increasing, thereby driving the growth of the market.

Asia Pacific is also expected to witness significant growth in the global anticoagulant market due to the increase in prevalence of cardiovascular diseases and increase in demand for anticoagulants in the region. For instance, anticoagulants play an important role in the treatment of cardiovascular diseases (CVDs). India has one of the highest burdens of cardiovascular disease (CVD) worldwide. As per the National Center for Biotechnology Information, the annual number of deaths from CVD in India is expected to increase from 2.26 million (1990) to 4.77 million (2020). This in turn has increased the demand for anticoagulants in this region.

Figure 1. Global Anticoagulant Market Share (%), by Region, 2022

Anticoagulant  | Coherent Market Insights

Global Anticoagulant Market Drivers:

Growing prevalence of chronic diseases across the globe is expected to boost the growth of global anticoagulant market during the forecast period. For instance, direct oral anticoagulants (DOACs) are used to prevent and treat cardiovascular disease. DOACs are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death across the world, taking an estimated 17.9 million lives each year. This in turn is expected to increase the demand for anticoagulants around the world.

Increase in demand for anticoagulants around the world is expected to propel growth of the global anticoagulant market during the forecast period. For instance, in December 2020, Natco Pharma announced the launch of an anti-blood clot tablet, named Rivaroxaban, to treat and prevent blood clots. Rivaroxaban is currently sold by Bayer under brand name of Xarelto in the Indian market. Natco has launched RPIGAT in four strengths, 20 mg, 15 mg, 10 mg, and 2.5 mg. The novel oral anti-coagulant, Rivaroxaban, is in line with Natco’s mission of affordable medicines accessible to all, a release from Natco Pharma said.

Global Anticoagulant Market Opportunities:

Rise in focus on the development of novel anticoagulants is expected to provide significant growth opportunities for players in the global anticoagulant market. For instance, with the rise in burden of chronic diseases worldwide, the demand for safe and effective anticoagulants is also increasing with the rapid pace. In March 2021, The U.S. National Institutes of Health (NIH) initiated the last of three Phase III clinical trials of blood thinners (anticoagulant) to prevent life-threatening blood clots in adults with COVID-19 (coronavirus disease).

Growing geriatric population across the globe is expected to offer lucrative growth opportunities for players in the global anticoagulant market. For instance, the demand for improvised and non-invasive treatments is rising among geriatric population, which in turn has increased the demand for anticoagulants worldwide. According to the World Health Organization (WHO), by 2030, 1 in 6 people in the world will be aged 60 years or over, and by 2050, the world’s population of people aged 60 years and older will double (2.1 billion).

CMI table icon

Anticoagulant Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2021: US$ 30,773.2 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2028
Forecast Period 2022 to 2028 CAGR: 9.4% 2028 Value Projection: US$ 57,337.5 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Class: Novel Oral Anticoagulants (NOACs), Heparin and Low-molecular- weight Heparin(LMWH), and Vitamin K Antagonist
  • By Application: Atrial Fibrillation/Myocardial Infarction (Heart Attack), Deep Vein Thrombosis (DVT), Pulmonary Embolism, and Other Applications
Companies covered:

Pfizer Inc., Sanofi SA, Dr. Reddy’s Laboratories, Aspen Holdings, Abbott Laboratories, Leo Pharma AS, Alexion Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company, Daiichi Sankyo Company, and Boehringer Ingelheim Pharmaceuticals Inc., among others.

Growth Drivers:
  • Growing prevalence of chronic diseases across the globe
  • Increase in demand for anticoagulants around the world
Restraints & Challenges:
  • Side effects associated with some anticoagulant
  • Stringent government regulations

Global Anticoagulant Market Trends:

There is an increase in demand for direct oral anticoagulants across the world. The development and introduction of direct oral anticoagulants (DOACs) represent a huge advancement in the field of anticoagulation. Moreover, the adoption of novel oral anticoagulants (NOACs) is increasing or has increased in developing countries, and is anticipated to show a similar trend over the forecast period owing to the high preference of NOACs over the warfarin.

Moreover, the use of anticoagulants is increasing, owing to the increasing usage of plasma in the pharmaceutical industry. Apart from this, they are being used in a variety of clinical applications. These wide-ranging applications range from anti-tumor and anti-inflammatory to the prevention of infectious disease and the use as nano-carriers for drug delivery. This trend is also expected to continue over the forecast period, driving the market growth.

Global Anticoagulant Market Restraints:

Side effects associated with some anticoagulant are expected to hamper the growth of the global anticoagulant market. For instance, anticoagulant medications can cause side effects that may lead to more serious complications. The most common side effect associated with any anticoagulant is bleeding. Depending on the medicine used, other potential risks exist. They can also cause nausea, upset stomach, and diarrhea, among others.

Stringent government regulations are expected to hinder growth of the anticoagulant market. The usage of oral anticoagulants is being monitored for adverse drug events. For instance, the United States Food Drug Administration (FDA) uses standard surveillance definitions for anticoagulant-related bleeding events in post-marketing and/or epidemiologic analyses, to access the accuracy of diagnostic and procedural coding to capture anticoagulant-related bleeding events.

Figure 2. Global Anticoagulant Market Share (%), by Drug Class, 2022

Anticoagulant  | Coherent Market Insights

Global Anticoagulant Market Segmentation:

The global anticoagulant market report is segmented into Drug Class, Application, and Geography.

Based on Drug Class, the market is segmented into Novel Oral Anticoagulants (NOACs), Heparin and Low-molecular- weight Heparin (LMWH), and Vitamin K Antagonist). Out of which, Novel Oral Anticoagulants (NOACs) Segment is expected to dominate the anticoagulant market over the forecast period and this is attributed to the increase in adoption of novel oral anticoagulants. NOACs can help prevent clots from being formed and protect one from certain types of strokes.

Heparin and Low-Molecular-Weight Heparin (LMWH) Segment is also expected to witness significant growth in the near future and this is owing to the increase in burden of chronic diseases. LMWH is used to treat cancer-related blood clots, as it is more effective than warfarin.

Based on Application, the market is segmented into Atrial Fibrillation/Myocardial Infarction (Heart Attack), Deep Vein Thrombosis (DVT), Pulmonary Embolism, and Other Applications. Out of which, Atrial Fibrillation/Myocardial Infarction (Heart Attack) Segment is expected to dominate the market during the forecast period and this is attributed to the increase in incidence of cardiovascular diseases (CVDs) across the globe.

Deep Vein Thrombosis (DVT) Segment is also expected to witness significant growth in the near future and this is owing to the increase in usage of anticoagulants. Anticoagulant therapy remains the mainstay of medical therapy for deep venous thrombosis (DVT).

Global Anticoagulant Market: Key Developments

In October 2019, Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved Xarelto (Rivaroxaban) for the prevention of venous thromboembolism (VTE).

In March 2019, Bristol-Myers Squibb-Pfizer Alliance announced results of Phase 4 AUGUSTUS trial evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs) in individuals with non-valvular atrial fibrillation (NVAF) and recent acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI).

Global Anticoagulant Market: Key Companies Insights

The global anticoagulant market is highly competitive. This is attributed to the rise in demand for or increase in adoption of anticoagulants around the world, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global anticoagulant market are Pfizer Inc., Sanofi SA, Dr. Reddy’s Laboratories, Aspen Holdings, Abbott Laboratories, Leo Pharma AS, Alexion Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company, Daiichi Sankyo Company, and Boehringer Ingelheim Pharmaceuticals Inc., among others.

*Definition: Anticoagulants are a class of drugs that help prevent blood clots. They're given to people at a high risk of getting clots, to reduce the chances of developing serious conditions such as strokes and heart attack. They are used to prevent and treat cardiovascular disease.

Anticoagulants are a class of drugs that help prevent blood clots. They are commonly called blood thinners. They're given to people at a high risk of getting clots, to reduce the chances of developing serious conditions such as strokes and heart attack. Anticoagulants are commonly used to prevent and treat cardiovascular diseases (CVDs).

Market Dynamics:

Growing prevalence of chronic disease, rise in demand for anticoagulants, increase in focus on the development of novel anticoagulants, and growing geriatric population across the globe are major factors expected to drive growth of the global anticoagulant market.

For instance, in June 2022, Apotex Inc. announced the launch of APO-Apixaban tablets, Canada's first generic alternative to Eliquis. Apixaban is an oral anticoagulant indicated for the prevention and treatment of harmful blood clots.

Moreover, in June 2021, the Food and Drug Administration (FDA) approved Pradaxa (dabigatran etexilate) oral pellets to treat children three months to 12 years old with venous thromboembolism. FDA also approved Pradaxa oral pellets to prevent recurrent clots among patients 3 months to less than 12 years old who completed treatment for their first venous thromboembolism.

Key features of the study:

  • This report provides in-depth analysis of the global anticoagulant market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global anticoagulant market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer Inc., Sanofi SA, Dr. Reddy’s Laboratories, Aspen Holdings, Abbott Laboratories, Leo Pharma, Alexion Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company, Daiichi Sankyo Company, and Boehringer Ingelheim Pharmaceuticals Inc., among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global anticoagulant market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anticoagulant market.

Detailed Segmentation:

  • Global Anticoagulant Market, By Drug Class:
    • Novel Oral Anticoagulants (NOACs)
    • Heparin and Low-molecular- weight Heparin(LMWH)
    • Vitamin K Antagonist
  • Global Anticoagulant Market, By Application:
    • Atrial Fibrillation/Myocardial Infarction (Heart Attack)
    • Deep Vein Thrombosis (DVT)
    • Pulmonary Embolism
    • Other Applications
  • Global Anticoagulant Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • Pfizer Inc.
    • Sanofi SA
    • Dr. Reddy’s Laboratories
    • Aspen Holdings
    • Abbott Laboratories
    • Leo Pharma AS
    • Alexion Pharmaceuticals Inc.
    • Bayer AG
    • Johnson & Johnson
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company
    • Boehringer Ingelheim Pharmaceuticals Inc.

Frequently Asked Questions

The global anticoagulant market size is estimated to be valued at US$ 33,514.6 Million in 2022 and is expected to exhibit a CAGR of 9.4% between 2022 and 2028.
Growing prevalence of chronic diseases and increase in demand for anticoagulants around the world is fueling the market.
The novel oral anticoagulants (NOACs) segment is the leading drug class segment in the market.
Side effects associated with some anticoagulants and stringent government regulations are major factors restraining the market.
Major players operating in the market are Pfizer Inc., Sanofi SA, Dr. Reddy’s Laboratories, Aspen Holdings, Abbott Laboratories, Leo Pharma AS, Alexion Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company, Daiichi Sankyo Company, and Boehringer Ingelheim Pharmaceuticals Inc., among others.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo